MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Sofosbuvir

CAS No. : 1190307-88-0

MCE 国际站：Sofosbuvir

产品活性：Sofosbuvir (GS-7977) 是 HCV RNA复制抑制剂，EC₅₀ 为 92 nM。

研究领域：Anti-infection

作用靶点：HCV

In Vitro: When cathepsin A (CatA) is incubated with PSI-7977 or Sofosbuvir (PSI-7977) for 150 min, ~18-fold more PSI-352707 is formed when Sofosbuvir (PSI-7977) is the substrate compared with PSI-7976. Moreover, the catalytic efficiency for Sofosbuvir (PSI-7977) with CatA is ~30-fold higher than that for PSI-7976. The genotype coverage of Sofosbuvir (PSI-7977) by using GT 1b (Con1)-, 1a (H77)-, and 2a (JFH-1)-derived replicons and GT 1b chimeric replicons containing the NS5B region from the J6 GT 2a isolate and from GT 2b and GT 3a patient isolates is evaluated, Sofosbuvir (PSI-7977) inhibits the replication of these replicons with similar EC₅₀s (between 16 and 48 nM), and is especially active against the chimeric replicon containing the J6 NS5B (EC₅₀=4.7 nM). Sofosbuvir (PSI-7977) inhibits clone A (GT 1b) wild-type and S282T replicons with EC₉₀ values of 0.42 and 7.8 μM, respectively. In the clone A replicon assay, Sofosbuvir (PSI-7977) produces anti-HCV activity with EC₉₀ values 0.42 μM.

相关产品：Covalent Screening Library Plus  |  Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Anti-Infection Compound Library  |  FDA-Approved Drug Library  |  Antiviral Compound Library  |  Drug Repurposing Compound Library  |  Covalent Screening Library  |  Nucleotide Compound Library  |  Anti-COVID-19 Compound Library  |  NMPA-Approved Drug Library  |  Orally Active Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Anti-Hepatitis C Virus Compound Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Rare Diseases Drug Library  |  Children’s Drug Library  |  EMA-Approved Drug Library  |  Non-steroidal Anti-Inflammatory Compound Library  |  Heterocyclic Compound Library  |  Sofosbuvir impurity J  |  Alisporivir  |  PSI-7409 tetrasodium  |  Dasabuvir  |  FNC-TP  |  DDX3-IN-1  |  Monodes(N-carboxymethyl)valine Daclatasvir  |  NHC-triphosphate tetraammonium  |  Sofosbuvir-d₆  |  Grazoprevir potassium salt  |  Daclatasvir-d₁₆  |  Deferiprone  |  Dehydrojuncusol  |  Daclatasvir dihydrochloride  |  Ribavirin  |  RO8191  |  Mecarbinate  |  Cyclo(Phe-Pro)  |  Sofosbuvir impurity G  |  NHC-diphosphate triammonium  |  Saikosaponin B2  |  Filibuvir  |  HCV-IN-33  |  Elbasvir  |  Platycodin D3  |  ISIS 14803  |  PQDVKFP  |  Yimitasvir

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物  |  寡核苷酸  |  抗体  |  点击化学

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。